Tao Y X, Shi Y K
Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Zhonghua Zhong Liu Za Zhi. 2021 Sep 23;43(9):917-923. doi: 10.3760/cma.j.cn112152-20200623-00591.
Hodgkin's lymphoma (HL) is a unique malignancy in which rare malignant Hodgkin and Reed-Sternberg (HRS) cells are scattered in the inflammatory cell rich microenvironment. This extensive but ineffective inflammatory cell infiltrate indicates that HRS cells have developed mechanisms to evade immune surveillance. The immune escape mechanisms of HL provide prognostic biomarkers and opportunities to develop new drugs. The immune evasion mechanisms in Hodgkin lymphoma include a reduction of human leukocyte antigen (HLA) to affect first signal which is essential for T cell activation; an upregulation of negative co-stimulatory molecules to inhibit T cell activation; resistance to apoptosis or killing by expressing some molecules on HRS cells membrane; an immunosuppressive network formed by HRS cells regulating the microenvironment immune cells. Immune escape mechanisms of HRS cells provide new targets for the development of new drug and the new drug development strategies include drugs on HRS cells and drugs on microenvironment.
霍奇金淋巴瘤（HL）是一种独特的恶性肿瘤，其中罕见的恶性霍奇金和里德-斯腾伯格（HRS）细胞散布在富含炎症细胞的微环境中。这种广泛但无效的炎症细胞浸润表明HRS细胞已形成逃避免疫监视的机制。HL的免疫逃逸机制提供了预后生物标志物以及开发新药的机会。霍奇金淋巴瘤的免疫逃避机制包括减少人类白细胞抗原（HLA）以影响对T细胞激活至关重要的第一信号；上调负性共刺激分子以抑制T细胞激活；通过在HRS细胞膜上表达某些分子来抵抗凋亡或杀伤；由HRS细胞形成的调节微环境免疫细胞的免疫抑制网络。HRS细胞的免疫逃逸机制为新药开发提供了新靶点，新药开发策略包括针对HRS细胞的药物和针对微环境的药物。
